Axicabtagene ciloleucel is indicated for:
Population group: both men and women, only adults (18 - 65 years old)
Αxicabtagene ciloleucel is indicated for the treatment of adult patients with primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 - 65 years old)
Αxicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):